

This report is going to take a comprehensive look into the company Pressure BioSciences Inc and its business.

COMPANY BACKGROUND

Pressure BioSciences Inc (OTCMKTS:PBIO) is one of the major players in developing, selling, and enabling pressure based platforms that can be deployed throughout the world in the field of life sciences. The company has managed to come up with a total of three pressure based platform, all of which are patented. One of those is the Ultra Shear Technology, the other is Pressure Cycling Technology and the third one is the Bare Fold Platform. The three different platforms offer three different types of services to life sciences companies and all of these have managed to gain considerable traction among life sciences companies all over the world.

PRODUCTS AND SERVICES

In order to get a better idea about the company, it is necessary for investors to have a good idea about the nature of the products and services that it offers. While it is true that Pressure BioSciences Inc is perhaps more of a services-oriented company, it does have some interesting products as well.



One of those is Barocycler 2320EXT. It is a product that is meant for PCT-HD and other forms of applications. The product comes with its fair share of state-of-the-art features like data logging and touch screen programming as well. In addition to that,

KEY STATISTICS

Price as of 11/01/21	\$2.52
52-Week High - Low	\$1.29 - \$4.98
Est Shares Outstanding	4.16M
Market Capitalization	\$16.05M
Average Volume	1,03,792
Exchange	OTCQB

Source: Yahoo Finance / OTC Markets

RECENT NEWS

September 30, 2021 - PBIO announced the successful application of its Ultra Shear Technology™ ("UST™") platform for the development of safe, natural, and environmentally friendly pesticides for the mitigation of agricultural losses and decreased spread of disease by insects.

September 29, 2021 - PBIO announced it is advancing rapidly on plans to establish West and East Coast demonstration and tolling sites in the United States. The Company is currently in discussions with potential business partners to fulfill certain strategic objectives, including: (i) accelerating demonstrations of its patented Ultra Shear Technology™ ("UST™") platform for processing nanoemulsions, and (ii) developing GMP-compliant toll manufacturing capacity to provide efficient and readily available fee-for-service production demands from small to medium scale manufacturers.

there are circulating water bath hookups as well as an electric heater. The maximum pressure that it can apply stands at a powerful 45000 psi. Anyone interesting in buying the product could consider visiting the Pressure BioSciences Inc website.

On the other hand, there are certain technologies that the company offers its clients and it could be a good move for any potential investor to look into some of those. One of the technologies that Pressure BioSciences Inc offers is BaroFold Technology. As mentioned earlier, it is a patented technology and helps in applying high pressure that is meant for controlled refolding as well as disaggregation of proteins to the native structures. The technology enhances the dissolution of protein aggregates and thereby helps in improving the activity of protein based therapeutics.

These are some of the products and services that have helped Pressure BioSciences Inc emerge as one of the leaders in its industry. However, the company is in fact striving to come up with new products and services in the near future so that it can continue to enjoy a degree of competitive advantage in an ultra-competitive industry.

INVESTMENT HIGHLIGHTS:-

Ultimately investors also need to see some of the reasons why they might consider looking into a company and its stock. In this context, there are three specific developments that they might consider looking into. Here is a look at some of the developments from recent times that could prove to be useful for any investor.

A. SUCCESSFUL TRANSFORMATION OF NEEM OIL

On September 30, Pressure BioSciences Inc had been in sharp focus among investors after it announced that its Ultra Shear Technology had been deployed successfully for the purposes of developing natural, environment-friendly, and safe pesticides for controlling agricultural losses. The company announced at the time that it had used its patented Ultra Shear Technology platform for the production of neem oil. Neem oil is a highly effective product that can be used to ward off insects and pests which spread diseases.

RECENT NEWS (Contd.)

September 28, 2021 - PBIO announced that the Company has accepted invitations to present at this week's Benzinga Healthcare and Emerging Growth Small Cap Conferences. These real-time, interactive investor conferences will feature presentations from multiple up-and-coming, innovative, and exciting small cap companies.

In addition to that, the neem oil that had been extracted by the technology is far more stable when compared to other forms of neem oil, which separate pretty quickly once it is mixed with water. Hence, the excitement among investors with regard to the development was understandable. It should be noted that in excess of 50% of the global population resides in regions where malaria is common and in such locations, the use of neem oil could prove to be highly beneficial. The product could eventually have widespread use and that may be the reason behind the excitement.

B. ANNOUNCEMENT OF FORWARD INTEGRATION PLANS

In October, the company made an announcement with regards to its plans for the establishment of East and West Coast demonstrations of Ultra Shear Technology. In addition to that, the company noted that it was also looking to bag Toll Manufacturing Partnerships in West and East Coasts of the country. Those are ambitious plans and could help the company in hitting the big time in a spectacular fashion. Hence, it is something that investors need to keep an eye on over the course of the coming weeks. In this context, it is also necessary to point out that back on October 1 the company had also announced that it was in talks with a large number of potential business partners who could fulfill specific strategic needs. Hence, this particular initiative from Pressure BioSciences Inc is another investment highlight that is hard to miss for anyone who may be tracking the company at this point in time.

C. KEY UPDATES TO SHAREHOLDERS


Last month on September 28, Pressure BioSciences Inc was in the news once again after it announced that it had accepted invitations for making presentations at the Benzinga Healthcare and Emerging Growth Small-Cap Conferences that were going to be held in the same week. Making presentations of that nature at key industry events helps in raising the profile of a company considerably due to the simple fact that more and more people get to know the company more intimately. The event in question was interactive in nature and it could be watched live by those who might have been interested. The Chief Executive Officer and President of Pressure BioSciences Inc Richard T Schumacher was scheduled to provide a corporate review at the event and was also meant to provide the audience with a lowdown of the revenues growth that had been seen in 2021.

These are three of the important events in recent times that is likely going to be on the minds of most investors when they start doing research on the Pressure BioSciences Inc stock a bit more deeply. This report seeks to provide investors with the correct perspective when it comes to Pressure BioSciences Inc.

MARKET OPPORTUNITY

Now that the investment highlights have been dealt with, it is perhaps important for investors to look into the market opportunities that exist for Pressure BioSciences Inc. The market opportunities will provide investors with a fair idea about the sort of growth that the company can expect to generate in the near term.

This brings us to the subject of the carotenoid algae known as Astaxanthin that is found in different forms of marine life like shrimp. It is one of the most potent natural antioxidants. Experts have revealed that it is 100 times more potent than Vitamin E and 6000 times more potent when compared to Vitamin C. This has caused a massive spike in demand for Astaxanthin all over the world and consequently the market has also grown considerably.



The market currently has a CAGR or compound annual growth rate of 13.3% and it has been suggested that the market could grow into a \$770 million one in the next three years. While many companies have been drawn to the Astaxanthin market, it seems it is Pressure BioSciences Inc that is in the unique position of actually cashing in on it. The Ultra Shear Technology that has been developed by the company could just be the thing that the Astaxanthin needs if it is to fulfill its potential.

The Ultra Shear Technology platform has the capability of producing molecules of Astaxanthin oil that are considered stable and of high quality. More importantly, the technology could make Astaxanthin far more bioavailable. If it is more bioavailable then it is going to make it cheaper to produce and at this point in time, bioavailability remains the biggest challenge for the nascent Astaxanthin industry. Hence, it is quite clear to see at this point in time that Pressure BioSciences Inc has the technology and the expertise to move in and corner a market with massive potential. It is something that investors could do well to keep an eye on in the coming months.

COMPETITIONS

There are very few companies that enjoy any kind of monopoly in the market and Pressure BioSciences Inc is not one of them. The company also has a fair share of competition in its particular niche and if it is to grow then it will need to handle its competition ably. Here is a look at some of the companies which are Pressure BioSciences Inc' competitors at this point in time.

AETHLON MEDICAL (NASDAQ:AEMD)

This is primarily a medical technology company and is focussed on the development of products by way of which life and organ threatening conditions could be diagnosed. At this point in time, the company is best known for having developed the product named Aethlon Hemopurifier, which is an immunotherapeutic device and helps in the removal of viruses from the human circulatory system that might be life-threatening.

ANIKA THERAPEUTICS INC (NASDAQ:ANIK)

Anika has a fairly large operation as a joint preservation company and operates through a range of subsidiaries. At this point, the company's operations are spread across Europe, the United States, and other parts of the world. The best-known products of the company currently are the two joint pain management products named Orthovisc and Monovisc. The other notable product from Anika is Cingal which provides both short-term and long-term pain relief.

ABIOMED INC (NASDAQ:ABMD)

Last but certainly not least, it is ABIOMED which poses serious competition to Pressure BioSciences Inc. It is a medical device company and is involved in the research, development, and eventual sales of products that help in the replacement of the pumping action of the heart. That is a massive market considering the fact that these products help in providing a continuum of care for patients who might have suffered from heart failure. The company is working on growing the extent of its offerings as well and that could be another reason why this is a rival that investors need to watch out for.

MANAGEMENT TEAM

A company might have excellent products and services on offer but without a capable management team, all of that might never reach its full potential. Here is a look at the key men in the management team at Pressure BioSciences Inc.

RICHARD T. SCHUMACHER, CHIEF EXECUTIVE OFFICER, AND DIRECTOR

Schumacher is the founder of the company and had been a director since 1978, when Boston Biomedica Inc, the legacy business had been established. He has been in his position as the CEO of the company since as far back as April of 2004 and has led the company with distinction during his tenure.

Prior to his association with the company, he had worked with the Center for Blood Research from 1972 through to 1985. He is a seasoned executive and one who knows the industry inside out.

EDMUND TING, SENIOR VICE PRESIDENT OF ENGINEERING

Edmund Ting joined the company in his present designation back in April of 2006 and has been an integral part of the management team since then. Prior to joining Pressure BioSciences Inc, Ting had been the Chief Research Officer at the high-pressure hydrostatic food industry processing equipment manufacturing company Avure Technologies.

ALEXANDER LAZAREV, CHIEF SCIENCE OFFICER

As the Chief Science Officer, Lazarev is perhaps one of the most important executives at Pressure BioSciences Inc. Like Ting, he had also joined the company back in April 2006 and at the time he had been the Director of Research and Development. Less than a year later in March 2007, he had been promoted to the post of Vice President of Research and Development. He has steadily risen up the ranks through his excellence as an executive and researcher and now oversees perhaps the most important aspect of the company.

CONCLUSION

As one can see, Pressure BioSciences Inc is a company that is currently at the forefront of innovation and has perfect market opportunities by way of which it could eventually emerge as a major player in the industry. While it is true that the company does face steep competition in the medical devices and platform industry, it also has its inherent competitive advantages that could help Pressure BioSciences Inc in holding its own in the long term. At the end of the day, the company is the owner of three patented technology platforms and as more and more applications of those technologies are discovered, it is going to be better for the company. Last but certainly not least, the company also boasts of an able management team and that is another factor that investors need to keep in mind when considering the Pressure BioSciences Inc stock.

COMPANY INFORMATION

Pressure BioSciences, Inc.

14 Norfolk Avenue, South Easton, MA 02375, United States

Web: www.pressurebiosciences.com

Email: info@pressurebiosciences.com

Phone: (508) 230-1828